Sprifermin Emerging Drug Insight and Market Forecast - 2032

This “Sprifermin Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about sprifermin for osteoarthritis in the six major markets. A detailed picture of the sprifermin for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the sprifermin for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the sprifermin market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.

Drug Summary

Sprifermin (AS-902330), also known as recombinant human fibroblast growth factor 18 (rhFGF18), is a recombinant form of human fibroblast growth factor 18 (FGF18), which is under development by Merck for the treatment of OA. As a recombinant form of FGF18, sprifermin is a potent agonist of FGFR2 and FGFR3. Sprifermin is delivered by injection into the joint every 6 or 12 months.

As the first recombinant form of human fibroblast growth factor 18 to demonstrate cartilage growth in a controlled clinical study, Sprifermin is at the forefront of next-generation regenerative medicine with the potential to modify the underlying disease pathology in OA.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the sprifermin description, mechanism of action, dosage and administration, research and development activities in osteoarthritis.
• Elaborated details on sprifermin regulatory milestones and other development activities have been provided in this report.
• The report also highlights the sprifermin research and development activities in osteoarthritis across the United States, Europe, Canada and Korea.
• The report also covers the patents information with expiry timeline around sprifermin.
• The report contains forecasted sales of sprifermin for osteoarthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for osteoarthritis.
• The report also features the SWOT analysis with analyst views for sprifermin in osteoarthritis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Sprifermin Analytical Perspective

In-depth Sprifermin Market Assessment

This report provides a detailed market assessment of sprifermin for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2025 to 2032.

Sprifermin Clinical Assessment

The report provides the clinical trials information of sprifermin for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence sprifermin dominance.
• Other emerging products for osteoarthritis are expected to give tough market competition to sprifermin and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of sprifermin in osteoarthritis.
• This in-depth analysis of the forecasted sales data of sprifermin from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the sprifermin in osteoarthritis.

Key Questions

• What is the product type, route of administration and mechanism of action of sprifermin?
• What is the clinical trial status of the study related to sprifermin in osteoarthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the sprifermin development?
• What are the key designations that have been granted to sprifermin for osteoarthritis?
• What is the forecasted market scenario of sprifermin for osteoarthritis?
• What are the forecasted sales of sprifermin in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, along with Canada and Korea?
• What are the other emerging products available and how are these giving competition to sprifermin for osteoarthritis?
• Which are the late-stage emerging therapies under development for the treatment of osteoarthritis?

This product will be delivered within 2 business days.